RCC: salvage ipilimumab-nivolumab combo shows antitumor activity

  • Gul A & al.
  • J Clin Oncol
  • 03.06.2020

  • von Deepa Koli
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Ipilimumab plus nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic renal cell carcinoma (RCC) who had prior treatment with checkpoint inhibition.

Why this matters

  • Ipilimumab plus nivolumab may be an effective salvage treatment option.
  • Further research is needed, however, to define durability of response and benefit vs risk.

Study design

  • 45 patients with metastatic RCC (median age, 62 years) who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab plus nivolumab.
  • Outcome: objective response rate, PFS, toxicity.

Key results

  • 38% of patients had brain metastasis.
  • The median time receiving prior immune checkpoint inhibitors was 13 months.
  • The median follow-up was 12 months.
  • The objective response rate was 20%.
  • 20% of patients had partial responses, and 16% had stable disease.
  • The median PFS was 4 (range, 0.8-19) months.
  • The median duration of response was 7 (range, 2-17) months.
  • 64% of patients experienced any grade and 13% had grade 3-4 immune-related adverse events.

Limitations

  • Small retrospective study.